These inhibitors are characterized by their ability to bind to different functional domains of the protein, thereby altering its structural conformation or its interaction with other molecules and substrates within the cell. Some inhibitors function by directly competing with the natural substrates of MUDENG, effectively reducing the protein's ability to catalyze reactions or interact with its intended targets. Others achieve inhibition by binding to allosteric sites, which changes the protein's configuration and diminishes its activity.
TMUDENG inhibitors also takes into account the possibility of covalent modification of amino acid residues that are critical for the enzyme's function. By forming irreversible or stable bonds with these key residues, some inhibitors can cause lasting inactivation of MUDENG. In addition to targeting the active site, MUDENG inhibitors can also act by hindering the association with necessary cofactors or by blocking the ATP binding sites, thereby depriving the protein of the energy required for its action. Another significant mode of inhibition involves the disruption of protein-protein interactions that are essential for MUDENG's biological role. Some inhibitors may even affect the protein's localization within the cell by interfering with membrane localization signals, which is crucial for the protein's proper function. Overall, the chemical diversity of MUDENG inhibitors is reflective of the complex nature of protein function regulation, with each inhibitor tailored to a specific aspect of MUDENG's structure or activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vioxx | 162011-90-7 | sc-208486 | 100 mg | $190.00 | 3 | |
Vioxx (Rofecoxib) selectively inhibits COX-2, reducing the formation of inflammatory prostaglandins without affecting COX-1, which is important for gastrointestinal protection. | ||||||
Etoricoxib | 202409-33-4 | sc-218446 | 10 mg | $36.00 | 3 | |
Etoricoxib selectively inhibits the enzyme COX-2, which is responsible for the synthesis of pro-inflammatory prostaglandins. | ||||||
Lumaricoxib | 220991-20-8 | sc-205736 sc-205736A | 100 mg 250 mg | $140.00 $280.00 | ||
Lumaricoxib selectively inhibits COX-2, reducing the production of prostaglandins involved in pain and inflammation. | ||||||
NS-398 | 123653-11-2 | sc-200604 sc-200604A | 5 mg 25 mg | $86.00 $339.00 | 9 | |
NS-398 is a selective inhibitor of COX-2, which prevents the formation of inflammatory prostaglandins. | ||||||